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Abstract
Background: The risk of infective endocarditis (IE) is markedly increased in patients receiving chronic hemodialysis
compared with the general population, but outcome data are sparse. The present study investigated causes and
risk factors of mortality in a hemodialysis-treated end-stage kidney disease- (ESKD) and a non-ESKD population with
staphylococcus (S.) aureus endocarditis.
Methods: Hemodialysis-treated ESKD patients with S. aureus endocarditis were identified from Danish National
Registries and Non-ESKD patients from The East Danish Database on Endocarditis. For establishing the cause of
death The Danish Registry of Cause of Death was used. Independent risk factors of outcome were identified in
multivariable Cox regression models.
Results: One hundred twenty-one hemodialysis patients and 190 non-ESKD patients with S. aureus endocarditis
were included during 1996–2012 and 2002–2012, respectively. The all-cause in-hospital mortality was 22.3% in
hemodialysis- and 24.7% in non-ESKD patients. One-year mortality, excluding in-hospital mortality, was 26.4% in
hemodialysis patients and 15.2% in non-ESKD patients.
The hazard ratio of all-cause mortality in hemodialysis was 2.64 (95% CI 1.70–4.10) at > 70 days after admission
compared with non-ESKD. Age (HR 1.03 (95% CI 1.02–1.04)) and diabetes mellitus (HR 2.17 (95% CI 1.54–3.10)) were
independent risk factors of all-cause mortality. The hazard ratio of cardiovascular death in hemodialysis was 3.20
(95% CI 1.78–5.77) at > 81 days after admission compared with non-ESKD. Age and diabetes mellitus were
independently related to cardiovascular death.
Conclusion: All-cause in-hospital mortality rates were similar in hemodialysis and non-ESKD patients with S. aureus
endocarditis whereas one-year mortality rates were significantly increased in the hemodialysis population.
Keywords: Staphylococcus aureus endocarditis, Hemodialysis, Mortality
Background
The risk of infective endocarditis (IE) is high in patients
with end-stage kidney disease (ESKD) [1]. Overall, the
most common microbial cause of IE in Denmark is
streptococcal species [2]. However, hemodialysis is associ-
ated with frequent staphylococcus (S.) aureus bacteremia.
The risk factors include repeated access to the vascular
system required for hemodialysis, a high frequency of
underlying heart valve disease and uremia related immune
impairment [3–7]. The all-cause in-hospital mortality has
been reported as high as 52% in hemodialysis patients
with IE and up to 56.3% at one-year follow-up [8–11].
Mitral valve disease and septic embolism have been
identified as mortality risk factors in hemodialysis pa-
tients with IE [12].
The all-cause in-hospital mortality of S. aureus endo-
carditis in the general population ranges between 15 and
22%, depending on the geographic region and study
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population [13–15]. Heart failure, age and cerebrovascu-
lar events are reported as mortality risk factors in the
general IE population [13, 15].
However, it remains to be clarified whether outcomes,
patient characteristics, cause of death and mortality risk
factors differ between hemodialysis- and non-ESKD S.
aureus endocarditis patients.
Therefore, the current study aimed to compare mortal-
ity, causes of death, and independent mortality risk factors
in hemodialysis-treated ESKD patients and non-ESKD pa-
tients with S. aureus endocarditis.
Methods
In Denmark, all residents are provided with a permanent
personal identification number that allows linkage be-
tween nationwide administrative registries on an individ-
ual level. Four of these registries were utilized to obtain
data. The Danish National Patient Registry includes in-
formation on all outpatient appointments and hospital
admissions including diagnoses and procedural codes in
Denmark, since 1978. Each admission and outpatient ap-
pointment is at discharge and at end of consultation
coded with one primary diagnosis, and if appropriate
one or more secondary diagnoses, according to the
International Classification of Diseases - until 1994 the
8th revision (ICD-8) was used and from 1994 the 10th
revision (ICD-10) has been applied [16]. The codes used
to retrieve comorbidities are considered valid [17]. All
deaths in Denmark are registered in The National Civil
Registry within 2 weeks from time of death. The Danish
Registry of Cause of Death holds information on cause
of death among deceased Danish residents in Denmark
on an individual level since 1970 and is coded according
to ICD-10, since 1994 [18]. The Danish National Regis-
try on Regular Dialysis and Transplantation was estab-
lished in 1990 and contains data on all Danish patients
receiving renal replacement therapy, including changes
in treatment modality and is considered valid [19].
Data in The East Danish Database on Endocarditis
was prospectively collected with consecutive enrolment
of patients diagnosed with IE from October 1st, 2002 to
December 31st, 2012, at two tertiary referral heart centers
in Copenhagen, Denmark. The centers cover a catchment
area of more than 2.4 million people. The diagnosis of IE
was based on clinical, microbiological and echocardio-
graphic findings evaluated according to the revised Duke
criteria [20]. The population has been described in more
details previously [21].
Population
The study comprised a hemodialysis population and a
non-ESKD population with S. aureus endocarditis.
The hemodialysis population was identified from
The Danish National Registry on Regular Dialysis and
Transplantation in the period from January 1st, 1996 to
December 31st, 2012.
Each hemodialysis patient was included at the first epi-
sode of IE after initiation of renal replacement therapy,
if caused by S. aureus. Patients were identified according
to hospital admission with discharge ICD-10 codes I33
and I38 as recorded in The Danish National Patient
Registry. The codes are considered accurate and valid
[22, 23]. Information on microbiology was based on
blood cultures retrieved from all Danish Departments of
Microbiology. Medical records were reviewed to collect
information on echocardiography and the involved heart
valves in each individual.
The non-ESKD population was identified from The
East Danish Database on Endocarditis. Patients with acute
kidney failure requiring temporary hemodialysis treatment
during admission were included in the cohort. Patients in
renal replacement therapy (hemodialysis, peritoneal dialy-
sis and kidney transplanted) were excluded from the
non-ESKD population.
Comorbidity
Data on comorbidity was derived from The Danish
National Patient Registry in a period of five years before index.
Outcome
The outcomes of interest were all-cause mortality as
well as mortality subdivided into cardiovascular- and
non-cardiovascular mortality. Cardiovascular death was
considered present when at least one diagnosis on the
death certificate was cardiovascular (I-diagnosis by ICD-10,
Additional file 1: Table S3). All subjects were followed until
death or end of study, December 31st, 2012.
Ethics
The study was approved by the Danish Data Protection
Agency (ref. 2007–58-0015 / internal ref. GEH-2014-015
I-suite no. 02733). Retrospective studies in registries do
not require ethical approval in Denmark.
Statistical analyses
Continuous variables were represented as mean +/−
standard deviation. Chi-square- and Fischer’s exact test
were used for analyses of differences between categorical
variables. Rank sum tests were used for differences be-
tween continuous variables. Cox proportional hazard
models were used to examine time from endocarditis to
death or study end. The following covariates were in-
cluded in the models: sex, age, diabetes mellitus and ex-
posure (hemodialysis, non-ESKD). The hazard ratio
between hemodialysis and non-ESKD changed (violation
of proportional hazard assumption) over time and was
therefore examined in discrete time periods of below
20 days, 20–70 days and at least 71 days for the outcome,
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all-cause mortality, and in time periods of below 26 days,
26–81 days and at least 82 days for the outcome, cardio-
vascular death. These periods were selected to represent
the first- and second quartile of outcome. Cumulative
incidence curves were depicted for all-cause mortality
and for the following end-points: cardiovascular death
and non-cardiovascular death accounting for competing
risks of death.
Sensitivity analyses were performed, excluding hemo-
dialysis patients switching renal replacement therapy mo-
dality during the study period, to validate the findings of
multivariable Cox regression and cumulative incidence.
All statistical analyses were performed using SAS ver-
sion 9.4 (SAS institute, Cary, NC, USA).
Results
Characteristics of the study population
Among a total number of 8791 hemodialysis patients,
121 patients with S. aureus endocarditis were identified
(Additional file 1: Tables S1 and S2). In non-ESKD
patients, 190 patients with S. aureus endocarditis were
included from the 977 IE patients in the East Danish
database on Endocarditis. Of these, 31 patients experienced
acute kidney failure during admission and received tempor-
ary hemodialysis treatment. Previous endocarditis was iden-
tified in 10 hemodialysis patients and 10 non-ESKD
patients. The mean age was 60.5 (+/-SD 15.2 years) in the
hemodialysis population and 62.3 (+/-SD 16.2 years) in the
non-ESKD population.
More males than females were hospitalized with S.
aureus endocarditis during the study period (p < 0.001).
Diabetes mellitus and peripheral vascular disease
were significantly more prevalent in hemodialysis-
than in non-ESKD patients. Baseline characteristics and
distributions of comorbidities are presented in Table 1
(Additional file 1: Table S3).
Mortality, cause of death and heart valve surgery
During the study period, all-cause mortality was higher in
hemodialysis- (80.2%) than in non-ESKD patients (56.8%),
(p < 0.001). Cardiovascular death was also higher in the
hemodialysis- (46.3%) than in the non-ESKD population
(32.1%), (p = 0.016). The mean follow-up was 2.3 (+/-SD
2.8 years) in the study population.
The all-cause in-hospital mortality was similar, 22.3%
and 24.7% in hemodialysis- and non-ESKD patients, re-
spectively. The all-cause one-year mortality, excluding
in-hospital mortality, was higher in hemodialysis- than
in non-ESKD patients (p = 0.023), Table 2.
The mitral valve was most often affected in the
hemodialysis population, whereas infections of the mi-
tral- and aortic valves were more evenly distributed in
the non-ESKD patients, Table 3. All patients underwent
echocardiography. The proportion of transesophageal
echocardiography (TEE) was 70% in the hemodialysis
population and 92.6% in the non-ESKD population.
Information on echocardiography was not available in
nine hemodialysis patients.
A larger proportion of non-ESKD- than hemodialysis
patients underwent heart valve surgery during admission.
The one-year mortality subsequent to surgical treatment
was higher in the hemodialysis population than in the
non-ESKD population, Table 4. In the non-surgically
treated patients, the mortality at one year follow-up was
48.5% in the hemodialysis population and 43.3% in the
non-ESKD population. In the non-surgically treated
hemodialysis patients the mitral valve was infected in
48.5% and the aortic valve in 22.8%, as compared with
20.1% and 38.1% in the non-ESKD patients, respectively.
Factors associated with mortality
After an initial period of similar all-cause mortality in
hemodialysis- and non-ESKD patients, the risk of all-cause
mortality in hemodialysis patients exceeded the all-cause
mortality risk in the non-ESKD population, Fig. 1.
Similarly, there was no initial difference in the risk of
cardiovascular- and non-cardiovascular death in the two
study populations, but after an initial period the risk of
cardiovascular death in hemodialysis patients exceeded
the risk in non-ESKD patients, Fig. 2.
The hazard ratios of all-cause mortality did not differ
between hemodialysis- and non-ESKD patients during
the first two time periods: < 20 days- and 20–70 days
after admission, but after 70 days, the risk of all-cause
mortality in hemodialysis patients increased significantly,
HR 2.64 (95% CI 1.70–4.10), compared with non-ESKD
patients. Diabetes mellitus and age were independently
associated with all-cause mortality. There was no associ-
ation between gender and all-cause mortality, Fig. 3.
Figure 4 shows the results of the adjusted multivariable
Cox regression for each end-point of death. The hazard
ratios of cardiovascular death were similar in both study
populations during the first two time periods: < 26 days-
and 26–81 days after admission. At the third time period
(> 81 days after admission), the risk of cardiovascular
death was increased in hemodialysis patients compared
with non-ESKD patients, HR 3.20 (95% CI 1.78–5.77).
Age and diabetes mellitus were significantly related to car-
diovascular death.
The associations between exposure (hemodialysis com-
pared with non-ESKD), gender, age and non-cardiovascular
death were statistically insignificant.
Sensitivity analyses
Ten hemodialysis patients with S. aureus endocarditis
changed treatment modality during follow-up to either
peritoneal dialysis or received kidney transplantation. Sensi-
tivity analyses were performed excluding these ten patients.
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The association between exposure (hemodialysis compared
with non-ESKD) and adverse end-points remained consist-
ent and the cumulative incidences remained unaltered.
The mortality at one year was 67.7% and 34.6% in the
31 non-ESKD patients with temporary hemodialysis
treatment and the remaining 159 non-ESKD patients
(p = 0.001), respectively. Sensitivity analysis was per-
formed, excluding the 31 non-ESKD patients with tem-
porary hemodialysis treatment. The association between
exposure (hemodialysis compared with non-ESKD) and
all-cause mortality remained valid.
Sensitivity analysis was performed, excluding 31 pa-
tients initiating hemodialysis during 1996–2001. The
HR of all-cause mortality in hemodialysis was 0.64
(95% CI 0.34–1.19) < 22 days, 0.83 (95% CI 0.44–1.56) at
22–70 days and 2.64 (95% CI 1.70–4.08) at > 71 days after
admission compared with non-ESKD. Thus, the associ-
ation between the exposure variable and all-cause mortal-
ity remained unaltered.
Discussion
There were two major findings in this study. First, in pa-
tients with S. aureus endocarditis in-hospital mortality was
high, but there was no difference between hemodialysis and
non-ESKD patients. Second, in patients discharged alive,
mortality remained high in the one-year follow-up period.
The one-year mortality in hemodialysis patients with S.
aureus IE remained at the same level as in-hospital and
higher than the annual mortality in the general Danish
dialysis population [24, 25]. In non-ESKD patients with
S. aureus IE, mortality declined by approximately one
third at one-year follow-up compared with the in-hospital
mortality.
Overall, the distribution of basic characteristics in
hemodialysis- and non-ESKD patients was similar, except
from the prevalence of diabetes and peripheral vascular dis-
ease, which were significantly higher in hemodialysis- com-
pared with non-ESKD patients. These differences in baseline
characteristics are common features of hemodialysis patients
Table 1 Baseline characteristics of study populations with Staphylococcus aureus endocarditis
Characteristics Hemodialysis
(n = 121)
Non-ESKD
(n = 190)
Total
(n = 311)
P value
Follow-up (years) 1.8 ± 2.4 2.6 ± 2.9 2.3 ± 2.8
Age (years) 60.5 ± 15.2 62.3 ± 16.2 61.6 ± 15.8 0.301
Female (N) 47 (39%) 52 (27.4%) 99 (31.8%) 0.045
Age (years) 57.9 ± 14.7 66.6 ± 17.4 62.5 ± 16.5 0.004
Male (N) 74 (61%) 138 (72.6%) 212 (68.2%) 0.045
Age (years) 62.1 ± 15.3 60.6 ± 15.6 61.2 ± 15.5 0.417
Pre-existing Heart valve disease
Aortic valve 17 (14.1%) 40 (21.1%) 57 (18.3%) 0.134
Mitral valve 12 (10%) 22 (11.6%) 34 (11%) 0.712
Comorbidity
Myocardial infarction 17 (14.1%) 22 (11.6%) 39 (12.5%) 0.598
Diabetes mellitus 43 (35.5%) 23 (12.1%) 66 (21.2%) < 0.001
Chronic obstructive lung disease 7 (5.8%) 7 (3.7%) 14 (4.5%) 0.410
Peripheral vascular disease 19 (15.7%) 12 (6.3%) 31 (10%) 0.012
Ischemic heart disease 32 (26.5%) 48 (25.3%) 80 (25.7%) 0.894
Cardiac arrythmia disorder 30 (24.8%) 36 (19%) 66 (21.2%) 0.255
Atrial flutter 25 (20.7%) 26 (13.7%) 51 (16.4%) 0.118
Chronic heart failure 30 (24.8%) 32 (16.8%) 62 (20%) 0.109
aChronic kidney disease stage
1 51 (26.8%)
2 52 (27.4%)
3 55 (28.9%)
4 25 (13.2%)
5 7 (3.7%)
5 dialysis 121 (100%) –
Values are given as mean, +/− SD or N (%)
aThe plasma creatinine level at admission was used to calculate the eGFR and the CKD-EPI creatinine equation was applied
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[1]. It is observed that the women in the hemodialysis popu-
lation are younger than the women in the non-ESKD popu-
lation, which remains to be explored further.
The present all-cause in-hospital mortality rate in
hemodialysis patients was comparable to findings in
other studies on hemodialysis and IE. In a large series of
13,130 hemodialysis patients with IE, Shroff et al. found
an in-hospital mortality rate of 23.5% [26]. In smaller
observational studies in-hospital- and 30 days mortality
were reported to be 14.3–31% [3, 8, 27, 28]. In a recent
Danish study, Ludvigsen et al. included 9392 hemodialysis
patients, of these 150 patients were diagnosed with IE
[29]. The thirty-day mortality was 15% in IE patients
undergoing hemodialysis, which is slightly lower than the
in-hospital mortality in the present study. The reported
thirty-day mortality in the study by Ludvigsen et al. is
based on IE regardless of bacterial etiology, which might
explain the observed difference.
The in-hospital mortality varied between 15 and 22%
in other recently studied populations [13–15], which is
in accordance with our current observation. However,
patients in renal replacement therapy were not excluded
from previous studies.
In the present study, the in-hospital mortality was
similar for hemodialysis- and non-ESKD patients. Like-
wise, Hsiao et al. found evenly distributed in-hospital
mortality in 39 hemodialysis patients (46.2%) and 51
non-ESKD patients (51%) with IE [30]. However, these
in-hospital mortality rates were markedly higher than those
in the present study. This difference might be caused by
non-comparable study populations. In our study, 70% of
hemodialysis patients underwent TEE. The sensitivity of
TEE is superior to transthoracic echocardiography (TTE)
not only in detecting perivalvular abscesses, −fistulas and
perforations, but also in detecting small vegetations
[31, 32]. The outcome of uncomplicated IE patients with
small vegetations is often good, and patients with compli-
cated IE who receive surgery have a definite better out-
come than complicated IE treated conservatively [33]. In
the study by Hsiao et al., the percentage of TEE is unclear
and only TTE data is referred. Thus, a lower proportion
of TEE may have led to selection bias in disease severity,
Table 3 Heart valve involvement in Staphylococcus aureus
endocarditis
Hemodialysis
(n = 121)
Non-ESKD
(n = 190)
Total
(n = 311)
Mitral valve 62 (51.2%) 50 (26.3%) 112 (36%)
Aortic valve 27 (22.3%) 72 (37.9%) 99 (31.8%)
Tricuspid valve 3 (2.5%) 13 (6.8%) 16 (5.1%)
Pulmonic valve – 1 (0.5%) 1 (0.3%)
Aortic- and mitral valve 3 (2.5%) 25 (13.2%) 28 (9%)
Aortic- and tricuspid valve – 1 (0.5%) 1 (0.3%)
Aortic- and pulmonic valve – 1 (0.5%) 1 (0.3%)
Mitral- and tricuspid valve 3 (2.5%) 1 (0.5%) 4 (1.3%)
Mitral- and pulmonic valve – 2 (1.1%) 2 (0.6%)
Cardiac device lead 5 (4.1%) 22 (11.6%) 27 (8.7%)
Right side 9 (7.4%) 2 (1.1%) 11 (3.5%)
Unavailable 9 (7.4%) – 9 (2.9%)
Values are given as N (%), − None
Table 2 In-hospital- and one-year mortality following Staphylococcus aureus endocarditis
In-hospital 1-year excluding in-hospital
Cause of Death Hemodialysis
(n = 121)
Non-ESKD
(n = 190)
P value Hemodialysis
(n = 121)
Non-ESKD
(n = 190)
P value
All-cause 27 (22.3%) 47 (24.7%) 0.683 32 (26.4%) 29 (15.3%) 0.023
Cardiovascular 14 (11.6%) 26 (13.7%) 0.729 18 (14.9%) 17 (8.9%) 0.123
Heart failure 2 (1.7%) 7 (3.7%) 4 (3.3%) 10 (5.3%)
Myocardial infarction – 2 (1.1%) 2 (1.7%) 1 (0.5%)
Stroke 3 (2.5%) 4 (2.1%) 4 (3.3%) 4 (2.1%)
aOther 9 (7.4%) 5 (2.6%) 13 (10.7%) 3 (1.6%)
Non-cardiovascular 13 (10.7%) 21 (11.1%) 0.932 11 (9.1%) 11 (5.8%) 0.298
Sepsis 10 (8.3%) 14 (7.4%) 5 (4.1%) 3 (1.6%)
Respiratory failure 3 (2.5%) 2 (1.1%) 3 (2.5%) 1 (0.5%)
ESKD – – 2 (1.7%) –
Diabetes mellitus – – 2 (1.7%) 1 (0.5%)
Gangrene – – – 1 (0.5%)
Unknown – 5 (2.6%) – 5 (2.6%)
Values are given as N (%), − None
aAortic valve disease, mitral valve insufficiency, ventricular fibrillation, vascular hypertension, cardiac arrest, atrial fibrillation, unclassified cardiovascular cause of
death subsequent to Staphylococcus aureus endocarditis
‡ESKD end-stage kidney disease
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by including patients with only larger vegetations and
unrecognized perivalvular complications, which in part
may explain their higher in-hospital mortality rates.
The all-cause one-year mortality in hemodialysis- and
non-ESKD patients was similar to other studies on IE. In
a single center study of 2239 hemodialysis patients from
the period 1990–2000, Maraj et al. identified 24 incident
cases of S. aureus endocarditis among 32 cases of IE
[34]. They found a one-year all-cause mortality of 56.3%
among all IE cases. In a study from the International
Collaboration on Endocarditis-cohort, Lauridsen et al.
reported the all-cause one-year mortality among patients
with left-sided native valve S. aureus endocarditis to
43%, which is consistent with the current non-ESKD
population [35]. Hemodialysis patients were not excluded
in the study by Lauridsen et al., but only accounted for
12% of their population.
Patients undergoing dialysis have remarkably high
one-year mortality. Cardiovascular disease is recognized as
the leading cause of death in dialysis patients [36] followed
by infections frequently related to the hemodialysis vascular
access [37]. Recurrent bacteremia due to impaired immune
function second to uremia [4] and the reduced defense
against bacteria following repeated access to the vascular
system dispose to increased risk of infections [38]. The
all-cause one-year mortality was 16–20% in the Danish dia-
lysis population in the period 2014–2015 [24, 25]. In a re-
cent study on a large European end-stage kidney disease
population from 1993 to 2007 with follow-up until 2012,
Vogelzang et al. demonstrated an all-cause long-term mor-
tality of 67% in the studied period with a median follow-up
of 3.7 years. Cardiovascular death accounted for 24.4%,
whereas infections were ascribed as the cause of death in
11% [39]. However, hemodialysis patients with S. aureus
endocarditis have an even higher one-year cardiovascular
mortality and a higher long-term cardiovascular and
all-cause mortality.
Left-sided involvement in IE is most common in
hemodialysis patients [11, 27, 28]. Calcification of the
aortic- and mitral valve is common in end-stage kidney
disease, which leads to altered local hemodynamics, in-
creasing the susceptibility for IE [40, 41]. The right sided
heart valves were involved in nine cases only in the
present hemodialysis population, which is consistent with
Fig. 1 Cumulative incidence of all-cause mortality according to exposure (hemodialysis in ESKD, non-ESKD)
Table 4 Heart valve surgery and mortality concomitant to Staphylococcus aureus endocarditis
Heart valve surgery Mortality
Total Mitral
valve
Aortic
valve
Tricuspid
valve
Pulmonic
valve
Aortic- and
mitral valve
Aortic- and
tricuspid valve
Mitral- and
tricuspid valve
In-hospital 1-year including
in-hospital
Hemodialysis 20 13 (65%) 4 (20%) – – 3 (15%) – – 4 (20%) 10 (50%)
Non-ESKD 56 23 (41.1%) 21 (37.5%) 3 (5.4%) 2 (3.6%) 5 (9%) 1 (1.8%) 1 (1.8%) 13 (23.2%) 18 (32.1%)
Values are given as N (%)
− None
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previous published data [11, 12, 27, 28]. It has been re-
ported that the mitral valve is most commonly involved in
left-sided IE in hemodialysis patients [11, 12, 27, 28],
which may be due to annular calcification of the mitral
valve [42]. In accordance with this observation we found
mitral valve endocarditis in 51.2% of the hemodialysis
patients.
Heart valve surgery was performed twice as often in the
non-ESKD population as in the hemodialysis population.
This difference may be explained by the high number of
comorbidities leading to increased risk of heart valve sur-
gery in hemodialysis patients. The in-hospital mortality
following surgery was similar in both populations, but dif-
fered at one-year follow-up. Restriction in selection of
hemodialysis patients eligible for surgery may explain the
similar in-hospital mortality. In other studies, in-hospital
mortality following heart valve surgery in hemodialysis pa-
tients has been varying (7–73%) [8, 12, 27, 43]. Differences
in patient selection and disease severity at the time of
intervention may be part of the explanation.
Fig. 3 Risk factors for all-cause mortality in Staphylococcus aureus endocarditis patients
Fig. 2 Cumulative incidence of cardiovascular death and non-cardiovascular death according to exposure (hemodialysis in ESKD, non-ESKD)
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Raza et al. [44] found a higher mortality at one-year
among surgically treated hemodialysis patients with IE
compared with a propensity matched group of non-ESKD
population and compared with the general hemodialysis
population. This is consistent with our data. However,
Raza et al. also found that mortality at one-year was higher
in the non-surgically treated hemodialysis population (70%)
with IE than in the surgically treated hemodialysis popula-
tion (44%). We found no difference in the one-year mortal-
ity in the operated- (50%) and the non-operated (48.5%)
hemodialysis patients.
The mortality rate related to mitral valve endocarditis
has recently been reported higher than in aortic valve
endocarditis. Surgical challenges related to invasive mitral
endocarditis compared with aortic valve surgery compli-
cate the surgical treatment and outcome of mitral valve
endocarditis [45]. The proportion of mitral valve endocar-
ditis was higher in the non-surgically treated hemodialysis
population reported by Raza et al. (62%) compared with
the present study (48.5%), which may explain a lower
mortality rate in our study.
Additional factors may contribute to this discrepancy.
Our study population was smaller and unmatched. Fur-
thermore, possible differences in distribution of methi-
cillin resistance S. aureus and geographical area may
explain the findings.
In non-ESKD patients, age, heart failure and cerebro-
vascular event have been described as risk factors of all-
cause death in IE [14, 15, 46]. In hemodialysis patients,
age, cerebrovascular event and diabetes mellitus have been
related to all-cause mortality [12, 26]. In line with these
previous data, diabetes mellitus and age were also related
to both all-cause- and cardiovascular mortality in the
current study. In addition, hemodialysis was associated
with increased risk of all-cause mortality and cardiovascu-
lar death 70- and 81 days after admission with hazard
ratios of 2.64 (95% CI 1.70–4.10) and 3.20 (95% CI
1.78–5.77) compared with non-ESKD patients, respect-
ively. These comparisons have not been reported before
and might be explained by a combination of frequent and
continuous calcification of heart valves and high preva-
lence of mitral valve involvement in infective endocarditis,
leading to progressive heart failure in the hemodialysis
population with IE [40].
Strengths and limitations
There are limitations inherent to the observational design
of the study population. Furthermore, the study popula-
tion is small and unmatched. However, the hemodialysis
cohort is nationwide and includes all chronic hemodialysis
patients with S. aureus endocarditis in Denmark in the
study period, based on a validated nationwide registry.
Additionally, each record for hemodialysis patients was
assessed to retrieve information on the microbiological
agent, echocardiography and infected heart valve. There
are some limitations in the non-ESKD cohort. It consists
of patients from two tertiary heart centers and is therefore
subject to referral bias. Complicated patients and those
eligible of surgery are referred to these centers, thus limit-
ing the generalizability of the results. However, it should
be noted that the two centers covered a catchment
area of > 2.4 million people. Information on methicillin re-
sistant Staphylococcus aureus (MRSA) is not available in
the national registries. However, the occurrence of MRSA
infection is low in Denmark [47].
Fig. 4 Risk factors for cardiovascular- and non-cardiovascular death in Staphylococcus aureus endocarditis patients
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Conclusions
In patients with S. aureus endocarditis, despite similar
in-hospital mortality, chronic hemodialysis treatment had
a marked negative impact on one-year all-cause- and
cardiovascular mortality as compared with non-ESKD
patients. This difference in mortality was significant within
3 months.
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